Spots Global Cancer Trial Database for Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
Official Title: Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment
Study ID: NCT04454476
Study Description
Brief Summary: This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.
Detailed Description: Objectives: * To evaluate the efficacy of Trametinib in reversing metaplasia in participants with Stage 1 gastric cancer * To evaluate the safety of Trametinibin in Stage I gastric cancer patients
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nagasaki University Hospital, Nagasaki, , Japan
Nihon University School of Medicine, Tokyo, , Japan
University of Tokyo Medical Center, Tokyo, , Japan
Contact Details
Name: James Goldenring, MD
Affiliation: Vanderbilt Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
